Physician Perceptions of the FDA’s Breakthrough Therapy Designation: An Update

The US Food and Drug Administration developed the Breakthrough Therapy designation to expedite the development and review of drugs that show a clear advantage over available therapy for serious conditions. Prior research has shown that physicians tend to misunderstand that a drug may receive a Break...

Descripción completa

Detalles Bibliográficos
Autores principales: Paquin, Ryan S, Boudewyns, Vanessa, O’Donoghue, Amie C, Aikin, Kathryn J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842303/
https://www.ncbi.nlm.nih.gov/pubmed/35305103
http://dx.doi.org/10.1093/oncolo/oyab021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842303/
https://www.ncbi.nlm.nih.gov/pubmed/35305103
http://dx.doi.org/10.1093/oncolo/oyab021

Ejemplares similares